<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00871689</url>
  </required_header>
  <id_info>
    <org_study_id>2008LS110</org_study_id>
    <secondary_id>MT2008-36</secondary_id>
    <secondary_id>0810M51781</secondary_id>
    <nct_id>NCT00871689</nct_id>
  </id_info>
  <brief_title>Chemotherapy, Total-Body Irradiation, Donor Natural Killer Cell Infusion, Aldesleukin, and UCB Transplant in Treating Patients With Relapsed or Refractory AML</brief_title>
  <official_title>Haploidentical Donor NK Cell Adoptive Therapy and Double T Cell Depleted Umbilical Cord Blood Transplantation With Post-Transplant IL-2 Immune Therapy For Refractory Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Masonic Cancer Center, University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Masonic Cancer Center, University of Minnesota</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Giving chemotherapy and total-body irradiation before a donor umbilical cord blood
      stem cell transplant helps stop the growth of cancer cells. It may also stop the patient's
      immune system from rejecting the donor's stem cells. When the healthy stem cells and natural
      killer cells from a donor are infused into the patient they may help the patient's bone
      marrow make stem cells, red blood cells, white blood cells, and platelets. Giving
      interleukin-2 (IL-2, aldesleukin) after transplant may stimulate the natural killer cells to
      kill any remaining cancer cells.

      PURPOSE: This phase II trial is studying the side effects of giving combination chemotherapy
      together with total-body irradiation followed by interleukin-2 (IL-2, aldesleukin), and
      umbilical cord blood transplant and to see how well it works in treating patients with
      relapsed or refractory acute myeloid leukemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  To determine the rate of neutrophil engraftment and grade III-IV acute graft-versus-host
           disease (GVHD) following a T cell depleted (TCD) umbilical cord blood (UCB)
           transplantation without post-transplant immunosuppression followed by administration of
           interleukin-2 (IL-2, aldesleukin) (every other day) days +3 to +13 to expand NK cells in
           vivo.

      Secondary

        -  To evaluate the safety of this regimen as assessed by monitoring the rates of graft
           failure, acute GVHD, and transplant-related mortality (TRM).

        -  To perform quantitative, phenotypic, and functional assessments of the in vivo expanded
           UCB-derived NK cells on (day +72).

        -  To assess clinical disease response (leukemia clearance and complete remission) and
           survival duration in these patients.

        -  To evaluate the tolerability of aldesleukin in these patients.

        -  To evaluate the tolerance of IL-2

      OUTLINE:

        -  Preparative regimen: Patients receive fludarabine phosphate intravenously (IV) over 1
           hour on days -7 to -5 and cyclophosphamide IV on days -7 and -6. Patients undergo
           total-body irradiation twice daily on days -5 to -2.

        -  Transplantation: Patients undergo T-cell depleted umbilical cord blood (UCB)
           transplantation on day 0.

        -  IL-2 (Aldesleukin) therapy: Patients receive aldesleukin subcutaneously on days +3 6
           doses every other day) and +60 (6 doses every other day).

      Patients are followed periodically for up to 2 years after transplant.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Due to graft failure.
  </why_stopped>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients With Neutrophil Engraftment</measure>
    <time_frame>Day 42</time_frame>
    <description>Number of patient with absolute neutrophils &gt;500*10^8/kg by 42 days post transplant.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patients With Grade III-IV Acute Graft-Versus-Host (GVHD) Disease</measure>
    <time_frame>Day 100 Post Transplant</time_frame>
    <description>Number of patients with Grade III-IV GVHD. Graft-versus-host disease (GVHD) is a complication that can occur after a stem cell or bone marrow transplant in which the newly transplanted material attacks the transplant recipient's body.
Acute GVHD usually happens within the first 3 months after transplant.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Primary Graft Failure</measure>
    <time_frame>Day 42</time_frame>
    <description>Incidence of graft failure defined as an absolute neutrophil count of less than 500/uL and a bone marrow that is less than 5% cellular (marrow aplasia) on day 42.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Acute Graft-Versus-Host (GVHD) Disease</measure>
    <time_frame>Day 100 Post Transplant</time_frame>
    <description>Number of patients with any grade of GVHD. Graft-versus-host disease (GVHD) is a complication that can occur after a stem cell or bone marrow transplant in which the newly transplanted material attacks the transplant recipient's body.
Acute GVHD usually happens within the first 3 months after transplant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Transplant-Related Death (TRD)</measure>
    <time_frame>1 Year Post Transplant</time_frame>
    <description>Number of patients whose death is related to study treatment received. TRD is defined as the number of patients that die without prior relapse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Complete Remission of Disease</measure>
    <time_frame>Day 100</time_frame>
    <description>Disease response will be measured by rate of leukemic clearance (clearance of blasts in blood at timepoint 0) and complete remission (less than 5% blasts and recovery of hematopoiesis).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Overall Survival</measure>
    <time_frame>Month 6</time_frame>
    <description>Average number of days the patients were alive after receiving UCB transplantation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Successful Natural Killer Expansion</measure>
    <time_frame>Day 72 Post Transplant</time_frame>
    <description>Successful in vivo donor NK cell expansion will be defined as an absolute circulating donor-derived NK cell count of &gt;100 cells/Î¼l.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Leukemia</condition>
  <arm_group>
    <arm_group_label>UCBT With Post-Transplant IL-2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive cyclophosphamide, fludarabine phosphate, total-body irradiation, T cell depleted umbilical cord blood transplantation (UCBT), followed by interleukin-2 (IL-2, aldesleukin) every other day beginning day +3 for a total of 6 doses and again on day +60 every other day for 6 doses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>aldesleukin</intervention_name>
    <description>IL-2 will be administered (9 million units; 5 million units if weight is less than 45 kg) every other day beginning on day +3 for a total of 6 doses and again on day +60 every other day for 6 doses.</description>
    <arm_group_label>UCBT With Post-Transplant IL-2</arm_group_label>
    <other_name>IL-2</other_name>
    <other_name>interleukin-2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>60 mg/kg over 1 hour intravenously (IV) on days -7 and -6.</description>
    <arm_group_label>UCBT With Post-Transplant IL-2</arm_group_label>
    <other_name>Cytoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine phosphate</intervention_name>
    <description>25 mg/m^2 intravenously (IV) over 1 hour on days -7 through -5.</description>
    <arm_group_label>UCBT With Post-Transplant IL-2</arm_group_label>
    <other_name>Fludarabine</other_name>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>umbilical cord blood transplantation</intervention_name>
    <description>On day 0, transplantation will occur with double T-cell depleted (TCD) umbilical cord blood (UCB) units</description>
    <arm_group_label>UCBT With Post-Transplant IL-2</arm_group_label>
    <other_name>UCBT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>total-body irradiation</intervention_name>
    <description>administered on days -5 through -2; 330 cGy daily</description>
    <arm_group_label>UCBT With Post-Transplant IL-2</arm_group_label>
    <other_name>TBI</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged 0 to 45 years who meet one of the following criteria:

               -  Primary induction failure defined as no complete remission (CR) after two or
                  three induction cycles (no blast limit).

               -  Relapsed acute myeloid leukemia (AML) with low disease burden

                    -  For patients 19 through 45 years of age: must have less than 10% marrow
                       blasts at time of enrollment for patients who did not receive re-induction
                       or measured at least 28 days from the start of re-induction therapy.
                       Patients who have relapsed more than 12 months following a prior
                       hematopoietic cell transplant (HCT) and did not reach CR following one
                       re-induction cycle but have less than 10% marrow blasts are eligible.

                    -  For patients 0 through 18 years of age: must have less than 50% marrow
                       blasts after no more than 3 induction attempts

               -  CR3 or greater. This will include CRp defined as CR without platelet recovery to
                  100,000/mcL.

               -  CR1 or CR2 with high risk features (therapy induced, prior myelodysplastic
                  syndrome (MDS) or myeloproliferative disease (MPD), high risk cytogenetic or
                  molecular phenotype) with no available alternate (sibling, URD or UCB) donors.

          -  Patients with prior central nervous system (CNS) involvement are eligible provided
             that it has been treated and is in remission. CNS therapy (chemotherapy or radiation)
             should continue as medically indicated during the protocol.

          -  Have acceptable organ function within 14 days of enrollment defined as:

               -  Renal: creatinine â¤ 2.0 mg/dL (adult patients) or calculated creatinine clearance
                  &gt; 40 ml/min (pediatric patients)

               -  Hepatic: bilirubin, AST/ALT, ALP â¤ 5 x upper limit of normal

               -  Pulmonary function: DLCOcorr &gt; 50% of normal, (oxygen saturation [&gt;92%] can be
                  used in child where PFT's cannot be obtained)

               -  Cardiac: left ventricular ejection fraction â¥ 45%

          -  Karnofsky score (adults) &gt; 70% or Lansky score &gt; 50% (pediatrics)

          -  Women of childbearing potential must agree to use adequate contraception (diaphragm,
             birth control pills, injections, intrauterine device [IUD], surgical sterilization,
             subcutaneous implants, or abstinence, etc.) for the duration of treatment.

          -  All patients will be questioned about prior exposure to antibody therapy (including
             OKT3, rituximab, trastuzumab, and gemtuzumab) without affect to eligibility. Patients
             with prior exposure will have a blood sample collected for human anti-mouse antibody
             (HAMA). For patients with no prior antibody therapy exposure, no further action will
             be taken.

          -  Not receiving prednisone or other immunosuppressive medications

          -  Voluntary written consent

        Exclusion Criteria:

          -  Active infection at time of enrollment or documented fungal infection within 3 months

          -  Evidence of HIV infection or known HIV positive serology

          -  Pregnant or breast feeding. The agents used in this study may be teratogenic to a
             fetus and there is no information on the excretion of agents into breast milk. All
             females of childbearing potential must have a blood test or urine study within 2 weeks
             prior to registration to rule out pregnancy.

          -  If â¤ 18 years old, prior myeloablative transplant within the last 6 months. If &gt; 18
             years old prior myeloablative allotransplant or autologous transplant

          -  Extensive prior therapy including &gt; 12 months of any alkylator chemotherapy (etoposide
             &gt;100 mg/m^2 x 5 days, cyclophosphamide &gt;1 gm/m^2 or mitoxantrone &gt;8 gm/m^2) delivered
             at 3-4 week intervals or &gt; 6 months alkylator therapy (as above) with extensive
             radiation (determined by Radiation Oncology, e.g. mantle irradiation for Hodgkin's)
             and/or prior radiation therapy that makes a patient ineligible for total body
             irradiation (TBI).

        Criteria for Second Course of IL-2 (begin day +60):

          -  No Graft-Versus-Host Disease (GVHD), active infection or any other severe medical
             co-morbidity

          -  Absolute neutrophil count (ANC) &gt; 1000 without growth factor support

          -  No grade 4 toxicity (except fevers) attributed to IL-2 during course #1
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael R. Verneris, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Masonic Cancer Center, University of Minnesota</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Minnesota Children's Hospital - Fairview</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 27, 2009</study_first_submitted>
  <study_first_submitted_qc>March 27, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 30, 2009</study_first_posted>
  <results_first_submitted>June 11, 2012</results_first_submitted>
  <results_first_submitted_qc>June 11, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 16, 2012</results_first_posted>
  <last_update_submitted>December 3, 2017</last_update_submitted>
  <last_update_submitted_qc>December 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>adult acute myeloid leukemia with 11q23 (MLL) abnormalities</keyword>
  <keyword>adult acute myeloid leukemia with inv(16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(15;17)(q22;q12)</keyword>
  <keyword>adult acute myeloid leukemia with t(16;16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(8;21)(q22;q22)</keyword>
  <keyword>recurrent childhood acute myeloid leukemia</keyword>
  <keyword>secondary acute myeloid leukemia</keyword>
  <keyword>childhood acute myeloid leukemia with 11q23 (MLL) abnormalities</keyword>
  <keyword>childhood acute myeloid leukemia with inv(16)(p13;q22)</keyword>
  <keyword>childhood acute myeloid leukemia with t(15;17)(q22;q12)</keyword>
  <keyword>childhood acute myeloid leukemia with t(16;16)(p13;q22)</keyword>
  <keyword>childhood acute myeloid leukemia with t(8;21)(q22;q22)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Aldesleukin</mesh_term>
    <mesh_term>Interleukin-2</mesh_term>
    <mesh_term>Vidarabine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study entry was open to patients aged 0 to 45 years regardless of gender or ethnic background at the University of Minnesota, Masonic Cancer Center.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Patients Receiving Double Umbilical Cord Blood Transplant</title>
          <description>Patients that receive myeloablative preparative regimen (allopurinol 300 mg by mouth Day -8 through +14; fludarabine 25 mg/m^2 intravenously on days -7 through -5; cyclophosphamide 60 mg/kg intravenously on days -7 and -6; total body irradiation 165 cGy*2 on days -4 through -2), 2 units T cell depleted umbilical cord blood transplant on day 0, followed by IL-2 every other day beginning day +3 and day +60 for a total of 6 doses.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Patients Receiving Double Umbilical Cord Blood Transplant</title>
          <description>Patients that receive myeloablative preparative regimen (allopurinol 300 mg by mouth Day -8 through +14; fludarabine 25 mg/m^2 intravenously on days -7 through -5; cyclophosphamide 60 mg/kg intravenously on days -7 and -6; total body irradiation 165 cGy*2 on days -4 through -2), 2 units T cell depleted umbilical cord blood transplant on day 0, followed by IL-2 every other day beginning day +3 and day +60 for a total of 6 doses.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.5" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Neutrophil Engraftment</title>
        <description>Number of patient with absolute neutrophils &gt;500*10^8/kg by 42 days post transplant.</description>
        <time_frame>Day 42</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Patients Receiving Double Umbilical Cord Blood Transplant</title>
            <description>Patients that receive myeloablative preparative regimen (allopurinol 300 mg by mouth Day -8 through +14; fludarabine 25 mg/m^2 intravenously on days -7 through -5; cyclophosphamide 60 mg/kg intravenously on days -7 and -6; total body irradiation 165 cGy*2 on days -4 through -2), 2 units T cell depleted umbilical cord blood transplant on day 0, followed by IL-2 every other day beginning day +3 and day +60 for a total of 6 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Neutrophil Engraftment</title>
          <description>Number of patient with absolute neutrophils &gt;500*10^8/kg by 42 days post transplant.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Primary Graft Failure</title>
        <description>Incidence of graft failure defined as an absolute neutrophil count of less than 500/uL and a bone marrow that is less than 5% cellular (marrow aplasia) on day 42.</description>
        <time_frame>Day 42</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Patients Receiving Double Umbilical Cord Blood Transplant</title>
            <description>Patients that receive myeloablative preparative regimen (allopurinol 300 mg by mouth Day -8 through +14; fludarabine 25 mg/m^2 intravenously on days -7 through -5; cyclophosphamide 60 mg/kg intravenously on days -7 and -6; total body irradiation 165 cGy*2 on days -4 through -2), 2 units T cell depleted umbilical cord blood transplant on day 0, followed by IL-2 every other day beginning day +3 and day +60 for a total of 6 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Primary Graft Failure</title>
          <description>Incidence of graft failure defined as an absolute neutrophil count of less than 500/uL and a bone marrow that is less than 5% cellular (marrow aplasia) on day 42.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Acute Graft-Versus-Host (GVHD) Disease</title>
        <description>Number of patients with any grade of GVHD. Graft-versus-host disease (GVHD) is a complication that can occur after a stem cell or bone marrow transplant in which the newly transplanted material attacks the transplant recipient's body.
Acute GVHD usually happens within the first 3 months after transplant.</description>
        <time_frame>Day 100 Post Transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Patients Receiving Double Umbilical Cord Blood Transplant</title>
            <description>Patients that receive myeloablative preparative regimen (allopurinol 300 mg by mouth Day -8 through +14; fludarabine 25 mg/m^2 intravenously on days -7 through -5; cyclophosphamide 60 mg/kg intravenously on days -7 and -6; total body irradiation 165 cGy*2 on days -4 through -2), 2 units T cell depleted umbilical cord blood transplant on day 0, followed by IL-2 every other day beginning day +3 and day +60 for a total of 6 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Acute Graft-Versus-Host (GVHD) Disease</title>
          <description>Number of patients with any grade of GVHD. Graft-versus-host disease (GVHD) is a complication that can occur after a stem cell or bone marrow transplant in which the newly transplanted material attacks the transplant recipient's body.
Acute GVHD usually happens within the first 3 months after transplant.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Transplant-Related Death (TRD)</title>
        <description>Number of patients whose death is related to study treatment received. TRD is defined as the number of patients that die without prior relapse.</description>
        <time_frame>1 Year Post Transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Patients Receiving Double Umbilical Cord Blood Transplant</title>
            <description>Patients that receive myeloablative preparative regimen (allopurinol 300 mg by mouth Day -8 through +14; fludarabine 25 mg/m^2 intravenously on days -7 through -5; cyclophosphamide 60 mg/kg intravenously on days -7 and -6; total body irradiation 165 cGy*2 on days -4 through -2), 2 units T cell depleted umbilical cord blood transplant on day 0, followed by IL-2 every other day beginning day +3 and day +60 for a total of 6 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Transplant-Related Death (TRD)</title>
          <description>Number of patients whose death is related to study treatment received. TRD is defined as the number of patients that die without prior relapse.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Complete Remission of Disease</title>
        <description>Disease response will be measured by rate of leukemic clearance (clearance of blasts in blood at timepoint 0) and complete remission (less than 5% blasts and recovery of hematopoiesis).</description>
        <time_frame>Day 100</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Patients Receiving Double Umbilical Cord Blood Transplant</title>
            <description>Patients that receive myeloablative preparative regimen (allopurinol 300 mg by mouth Day -8 through +14; fludarabine 25 mg/m^2 intravenously on days -7 through -5; cyclophosphamide 60 mg/kg intravenously on days -7 and -6; total body irradiation 165 cGy*2 on days -4 through -2), 2 units T cell depleted umbilical cord blood transplant on day 0, followed by IL-2 every other day beginning day +3 and day +60 for a total of 6 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Complete Remission of Disease</title>
          <description>Disease response will be measured by rate of leukemic clearance (clearance of blasts in blood at timepoint 0) and complete remission (less than 5% blasts and recovery of hematopoiesis).</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Grade III-IV Acute Graft-Versus-Host (GVHD) Disease</title>
        <description>Number of patients with Grade III-IV GVHD. Graft-versus-host disease (GVHD) is a complication that can occur after a stem cell or bone marrow transplant in which the newly transplanted material attacks the transplant recipient's body.
Acute GVHD usually happens within the first 3 months after transplant.</description>
        <time_frame>Day 100 Post Transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Patients Receiving Double Umbilical Cord Blood Transplant</title>
            <description>Patients that receive myeloablative preparative regimen (allopurinol 300 mg by mouth Day -8 through +14; fludarabine 25 mg/m^2 intravenously on days -7 through -5; cyclophosphamide 60 mg/kg intravenously on days -7 and -6; total body irradiation 165 cGy*2 on days -4 through -2), 2 units T cell depleted umbilical cord blood transplant on day 0, followed by IL-2 every other day beginning day +3 and day +60 for a total of 6 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Grade III-IV Acute Graft-Versus-Host (GVHD) Disease</title>
          <description>Number of patients with Grade III-IV GVHD. Graft-versus-host disease (GVHD) is a complication that can occur after a stem cell or bone marrow transplant in which the newly transplanted material attacks the transplant recipient's body.
Acute GVHD usually happens within the first 3 months after transplant.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Overall Survival</title>
        <description>Average number of days the patients were alive after receiving UCB transplantation.</description>
        <time_frame>Month 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Patients Receiving Double Umbilical Cord Blood Transplant</title>
            <description>Patients that receive myeloablative preparative regimen (allopurinol 300 mg by mouth Day -8 through +14; fludarabine 25 mg/m^2 intravenously on days -7 through -5; cyclophosphamide 60 mg/kg intravenously on days -7 and -6; total body irradiation 165 cGy*2 on days -4 through -2), 2 units T cell depleted umbilical cord blood transplant on day 0, followed by IL-2 every other day beginning day +3 and day +60 for a total of 6 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Overall Survival</title>
          <description>Average number of days the patients were alive after receiving UCB transplantation.</description>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.5" lower_limit="98" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Successful Natural Killer Expansion</title>
        <description>Successful in vivo donor NK cell expansion will be defined as an absolute circulating donor-derived NK cell count of &gt;100 cells/Î¼l.</description>
        <time_frame>Day 72 Post Transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Patients Receiving Double Umbilical Cord Blood Transplant</title>
            <description>Patients that receive myeloablative preparative regimen (allopurinol 300 mg by mouth Day -8 through +14; fludarabine 25 mg/m^2 intravenously on days -7 through -5; cyclophosphamide 60 mg/kg intravenously on days -7 and -6; total body irradiation 165 cGy*2 on days -4 through -2), 2 units T cell depleted umbilical cord blood transplant on day 0, followed by IL-2 every other day beginning day +3 and day +60 for a total of 6 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Successful Natural Killer Expansion</title>
          <description>Successful in vivo donor NK cell expansion will be defined as an absolute circulating donor-derived NK cell count of &gt;100 cells/Î¼l.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Patients were followed from Day 1 up to death ( within 6 months).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Patients Receiving Double Umbilical Cord Blood Transplant</title>
          <description>Patients that receive myeloablative preparative regimen (allopurinol 300 mg by mouth Day -8 through +14; fludarabine 25 mg/m^2 intravenously on days -7 through -5; cyclophosphamide 60 mg/kg intravenously on days -7 and -6; total body irradiation 165 cGy*2 on days -4 through -2), 2 units T cell depleted umbilical cord blood transplant on day 0, followed by IL-2 every other day beginning day +3 and day +60 for a total of 6 doses.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukoencephalopathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Progressive Disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CNS Demyelinating Disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="7" subjects_affected="2" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="6" subjects_affected="2" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="6" subjects_affected="2" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Sweats</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Skin disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Quantitative, phenotypic and functional assessment of the in vivo expanded UCB-derived NK cells on Day 72 were not performed. Patients were not well enough to provide research samples.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Michael Verneris, M.D.</name_or_title>
      <organization>Masonic Cancer Center, University of Minnesota</organization>
      <phone>612-626-2961</phone>
      <email>verneris@umn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

